아이뮨링즈(IMRX) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

Q: What kind of company is 아이뮨링즈(IMRX)?

아이뮨링즈(IMRX) belongs to the Healthcare sector and operates in the Biotechnology industry.

Q: What is the market cap of IMRX?

The market cap of IMRX is approximately $282M, ranking 3,781 within its sector.

Q: What is the 52-week high and low for IMRX?

IMRX has recorded a 52-week high of $10.08 and a low of $2.90.

IMRX

Immuneering Corp

7월 27일 4:00 PM ET (한국 7/28 05:00)

$4.36

+0.04 ▲ +0.93%

아이뮨링즈(IMRX) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$282M

스몰캡

P/E

배당수익률

없음

52주 위치

20%

저점 +50% · 고점 -57%

애널리스트

적극 매수

B-

Fundamental health

vs. 방어주 소형주· based on 2 axes

수익성

산출 불가 (적자)

성장

Top 62%

밸류에이션

데이터 부족

재무 안정

Top 23%

Index ⓘ	RUT	P/E ⓘ	-	EPS (ttm) ⓘ	-1.17	Insider Own ⓘ	14.02%	Shs Outstand ⓘ	64.7M	Perf Week ⓘ	1.63%
Market Cap ⓘ	0.28B	Forward P/E ⓘ	-	EPS next Y ⓘ	-15.47%	Insider Trans ⓘ	0.09%	Shs Float ⓘ	55.6M	Perf Month ⓘ	-3.75%
Enterprise Value ⓘ	0.13B	PEG ⓘ	-	EPS next Q ⓘ	-0.27	Inst Own ⓘ	47.37%	Short Float ⓘ	27.34%	Perf Quarter ⓘ	-27.81%
Income ⓘ	-0.05B	P/S ⓘ	-	EPS this Y ⓘ	12.32%	Inst Trans ⓘ	-4.33%	Short Ratio ⓘ	9.96	Perf Half Y ⓘ	-18.66%
Sales ⓘ	0.00B	P/B ⓘ	1.37	EPS next 5Y ⓘ	2.56%	ROA ⓘ	-41.01%	Short Interest ⓘ	15.21M	Perf YTD ⓘ	-33.74%
Book/sh ⓘ	3.19	P/C ⓘ	1.8	EPS past 3/5Y ⓘ	12.72% -13.77%	ROE ⓘ	-43.84%	52W High ⓘ	-56.75% ($10.08)	Perf Year ⓘ	7.39%
Cash/sh ⓘ	2.42	P/FCF ⓘ	-	Sales past 3/5Y ⓘ	-	ROIC ⓘ	-25.94%	52W Low ⓘ	50.34% ($2.90)	Perf 3Y ⓘ	-53.52%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	-	EPS Y/Y TTM ⓘ	40.79%	Gross Margin ⓘ	-	Volatility(W/M) ⓘ	5.83% 6.01%	Perf 5Y ⓘ	-
Dividend TTM ⓘ	-	EV/Sales ⓘ	-	Sales Y/Y TTM ⓘ	-	Oper. Margin ⓘ	-	ATR (14) ⓘ	0.28	Perf 10Y ⓘ	-
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	32.45	EPS Q/Q ⓘ	50.84%	Profit Margin ⓘ	-	RSI (14) ⓘ	40.16	Recom ⓘ	1
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	32.45	Sales Q/Q ⓘ	-	SMA20 ⓘ	-10.8% ($4.89)	Beta ⓘ	0.43	Target Price ⓘ	$18.17
Payout ⓘ	-	Debt/Eq ⓘ	0.02	Earnings ⓘ	2026/5/15	SMA50 ⓘ	-8.07% ($4.74)	Rel Volume ⓘ	0.3	Prev Close ⓘ	$4.32
Employees ⓘ	37	LT Debt/Eq ⓘ	0.02	EPS/Sales Surpr. ⓘ	16.67% -	SMA200 ⓘ	-20.26% ($5.47)	Avg Volume(3M) ⓘ	1.53M	Price ⓘ	$4.36
IPO ⓘ	2021/7/30	Option/Short ⓘ	Yes/Yes			Trades ⓘ	3535	Volume ⓘ	459,567	Change ⓘ	0.93%

Quarterly earnings trend SEC filings · USD

23.12*

24.3

24.6

24.9

25.3

25.6

25.9

26.3

Revenue Net income 최근 분기: 매출 - · 순이익 $-13M (YoY +11%)

* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Immuneering Corp (IMRX) Investment Analysis

What kind of company is Immuneering Corp?

아이뮨링즈(IMRX) 방어주

Healthcare · Biotechnology

Small-Cap — Low Volume, High Volatility

🧬 This is a clinical-stage oncology biotech developing Deep Cyclic Inhibitors that intermittently block tumor signaling pathways. Its lead candidate, atebimetinib, has entered late-stage clinical trials for first-line metastatic pancreatic cancer, with the company focusing on a precision oncology-based novel drug pipeline.

Learn more about Immuneering Corp →

Market Cap

$0.3B

Approx. KRW 0.4 trillion

⚖️ 0% of Samsung Electronics

Market Cap Rank3781

Employees37people

IPO2021/07/30

Current Price$4.36 ≈ 5,973원

📌 RUT · NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 15일 (금) · 장 시작 전 EPS +16.7%

🔔 Earnings release 2026년 3월 6일 (금) · 장 시작 전 EPS +42.4%

Is it profitable?

Financially sound but profitability is low

Losses or thin margins — early-stage growth or weakening competitiveness

Profitability — How efficiently it makes money

ROE

Annual return earned on shareholders' equity (15%+ is strong)

-43.8%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROA

Annual earnings relative to total company assets

-41.0%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROIC

Return generated per dollar invested in the business

-25.9%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.02

✓ Healthy debt

My positionMid-range

Low range Average High range

Biotechnology Median 0.05

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

32.45

✓ 우수

My positionTop 5%

Low range Average High range

Biotechnology Median 5.75

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

32.45

✓ 우수

My positionTop 5%

Low range Average High range

Biotechnology Median 5.47

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$18.17

현재가 대비 +316.7%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

내년 EPS 예상 성장률

-15.5%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

5년 EPS 예상 연평균

+2.6%

💡 장기 성장 전망. 15% 이상이면 고성장 기업

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Reliability

Beat estimates in 2 of the last 2 quarters

예상 상회

예상 부합

예상 하회

100%

상회 비율

+29.5%

평균 서프라이즈

2026.05.15

상회

실적 $-0.21 · 예상 $-0.25 +16.7%

2026.03.06

상회

실적 $-0.18 · 예상 $-0.31 +42.2%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth

Mid-range within the industry

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

+12.3%

양호

My positionMid-range

Low range Average High range

방어주 소형주 Median 4.7% · Top 42%

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

-15.5%

부진

My positionBottom 25%

Low range Average High range

방어주 소형주 Median 10.1% · Bottom 21%

5-Year EPS CAGR Outlook

Projected average annual EPS growth over the next 5 years

+2.6%

평균

My positionMid-range

Low range Average High range

방어주 소형주 Median 3.4% · Bottom 47%

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

+12.7%

평균

My positionMid-range

Low range Average High range

방어주 소형주 Median 16.1% · Bottom 47%

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

-13.8%

부진

My positionBottom 25%

Low range Average High range

방어주 소형주 Median 8.7% · Bottom 17%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Roughly in line with the market over the past year

IMRX +7.4% · S&P 500 +16.0%

Excess return vs. market (price-based, ex-dividends)

1-year basis

vs S&P 500

-8.6%p

slightly behind the market

vs Health Care (XLV)

-12.3%p

behind the sector average

Rank among peers

1-year return Lower-Mid (lower 29%) Based on 154 peers

Current position within 52-week range

Low (-50.3%p) High (-56.8%p)

Current price is 50.3% above the 52-week low and 56.8% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-36.0%

Annualized volatility

71.1%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴

Current diagnosis · 2026-07-27

Downtrend zone

Current price $4.36 below the midline ($4.89). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🔴

Current diagnosis · 2026-07-27

Bearish momentum holding

MACD -0.115 < Signal -0.028 in negative zone + Hist negative (-0.087). Weakness in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴

Current diagnosis · 2026-07-27

Bearish zone

RSI 39.8 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 6.3.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry

Cheap on Vs. Assets

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

🏢 Vs. Assets Cheap

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

1.37x

✓ Very cheap

My positionTop 5%

Low range Average High range

Biotechnology 소형주 median 3.34x · Top 1% — relatively cheap within the industry

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

Analyst target price (reference)

$18.17 vs. current price +316.7%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Biotechnology 소형주

Who owns it?

Ownership backdrop is unfavorable

Insider modest net buying +0.1% · Institutional net selling -4.3% · Short interest very high 27.3% · Short interest up +6.2pp over last 90d

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

+0.1%

Insiders little change

🏦 Institutions (funds & investors)

-4.3%

Institutions net selling

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 47.4%

Moderate institutional participation

Healthcare 소형주 Median 65.6%

🧑‍💼 Insiders 14.0%

Founder/management large holders (strong skin-in-the-game)

Healthcare 소형주 Median 17.6%

👤 Retail investors (estimated) 38.6%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

27.3%

Very high — strong short-side pressure

Healthcare 소형주 Median 11.2%

Past 90 days 📈 +6.2%p increase

Short interest days to cover

10.0 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 64.7M주

Float (tradable shares) 55.6M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding IMRX

ETFs with the highest weightings · 10 total shown

IWC

iShares Micro-Cap ETF

0.06%

$1.4B

MARS

Roundhill Space & Technology ETF

0.03%

$51M

IBB

iShares Biotechnology ETF

0.03%

$9.4B

IBBQ

Invesco Nasdaq Biotechnology ETF

0.02%

$76M

BIB

ProShares Ultra Nasdaq Biotechnology 2X Shares

0.02%

$82M

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
IMRX This Stock	$282.1M	-	1.4 ▲	-43.84% ▲	-	+0.9%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 아이뮨링즈(IMRX)?

아이뮨링즈(IMRX) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of IMRX?

The market cap of IMRX is approximately $282M, ranking 3,781 within its sector.

What is the 52-week high and low for IMRX?

IMRX has recorded a 52-week high of $10.08 and a low of $2.90.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.